Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

BACKGROUND: Metastatic colorectal cancer (mCRC) is commonly treated with 5-fluorouracil, folinic acid, and oxaliplatin or irinotecan. The multitargeted kinase inhibitor, regorafenib, was combined with chemotherapy as first- or second-line treatment of mCRC to assess safety and pharmacokinetics (prim...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Schultheis, B., Folprecht, G., Kuhlmann, J., Ehrenberg, R., Hacker, U. T., Köhne, C. H., Kornacker, M., Boix, O., Lettieri, J., Krauss, J., Fischer, R., Hamann, S., Strumberg, D., Mross, K. B.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2013
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3660081/
https://ncbi.nlm.nih.gov/pubmed/23493136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt056
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items